Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 6140896, 7 pages
Research Article

Plasmatic Soluble Receptor for Advanced Glycation End Products as a New Oxidative Stress Biomarker in Patients with Prosthetic-Joint-Associated Infections?

1Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy
2Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy
3IRCCS Galeazzi Orthopaedic Institute, Milan, Italy
4U.O.C SMEL-1 Patologia Clinica IRCCS Policlinico San Donato, San Donato, Milan, Italy
5Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, Milan, Italy
6Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy
7Department of Health Sciences, Università degli Studi di Milano, Milan, Italy

Correspondence should be addressed to Emanuela Galliera; ti.iminu@areillag.aleuname

Received 7 July 2017; Revised 28 September 2017; Accepted 25 October 2017; Published 13 December 2017

Academic Editor: Benoit Dugue

Copyright © 2017 Luca Massaccesi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Prosthetic joint infection (PJI) is the most common cause of failure of total joint arthroplasty, but a gold standard for PJI diagnosis is still lacking. Advanced glycation end products (AGEs) are proinflammatory molecules inducing intracellular oxidative stress (OS) after binding to their cell membrane receptors (RAGE). The aim of this study was to evaluate plasmatic soluble receptor for advanced glycation end products (sRAGE), as a new OS and infection marker correlating sRAGE to the level of OS and antioxidant defenses, in PJI, in order to explore the possible application of this new biomarker in the early diagnosis of PJI. Plasmatic sRAGE levels (by ELISA assay), plasma antioxidant total defenses (by lag time method), plasma reactive oxygen species (ROS), and thiobarbituric acid reactive substance (TBARS) levels (by colorimetric assay) were evaluated in 11 PJI patients and in 30 matched controls. ROS and TBARS were significantly higher () while plasma total antioxidant capacity and sRAGE were significantly lower () in patients with PJI compared to controls. Our results confirm the OS in PJI and show a strong negative correlation between the level of sRAGE and oxidative status, suggesting the plasmatic sRAGE as a potential marker for improving PJI early diagnosis.